Early involved in SBIR and remaining program active for some 15 years through several iterations of business focus, Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Long since having outgrown SBIR eligibility, the firm's bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. Repligen is the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody-based therapeutics. In upstream processes, the firm's XCell ATF systems and growth factors are used to accelerate and increase productivity during the cell culture stage of biologic drug manufacturing. In downstream processes, Repligen developed and market an innovative line of OPUS® chromatography columns that is delivered pre-packed with customers choice of resin for their bench-scale through clinical production-scale purification needs. Having been in acqusiiton mode several times through the years - five previous transactions - with the acquisition of TangenX in 2016, the firm also now manufacture single-use Sius TFF cassettes and hardware, used in downstream protein concentration and filtration processes. Repligens corporate headquarters are in Waltham, MA (USA) with manufacturing facilities located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany.
